Business Context and Reporting Period
This Form 8-K was filed by BioRestorative Therapies, Inc. on October 15, 2018. The report details the entry into a material definitive agreement and the appointment of a new executive officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation terms.
- Base Salary: $350,000 annually for the new Executive Vice President and Chief Strategy Officer.
- Performance Bonus: Up to 30% of the annual salary based on established goals.
- Severance: Six months of salary under certain circumstances.
- Equity Grant: Option to purchase 500,000 shares of common stock at an exercise price of $1.42 per share.
Material Changes
The primary material change is the appointment of Lance Alstodt as Executive Vice President and Chief Strategy Officer, effective October 15, 2018. Mr. Alstodt brings over 25 years of experience in the medical device, biopharmaceutical, and healthcare services sectors, including a background in investment banking and founding MedVest Consulting Corporation.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of general business risks. However, the equity grant includes specific vesting milestones tied to operational progress:
- Tranche 1: 100,000 options vested immediately on the grant date.
- Tranche 2: 150,000 options vest on the earlier of the first anniversary of the grant date or the date of initial patient recruitment for the Company's Phase II lumbar clinical trial.
- Tranche 3: 250,000 options vest on the second anniversary of the grant date.
The option is exercisable for a period of ten years.
Investor Verification Checklist
- Verify the full text of the Employment Agreement (Exhibit 10.1) and Stock Option Agreement (Exhibit 10.2) for complete terms and conditions.
- Confirm the specific performance goals required to trigger the 30% bonus.
- Monitor the status of the Phase II lumbar clinical trial to determine the vesting date for the second tranche of stock options.
- Review the Company's 2010 Equity Participation Plan to understand the broader context of the equity grant.